Beta-defensin peptide (None)

Beta-defensin peptides are a rapidly evolving family of small, cationic, cysteine-rich peptides essential for innate immune defense, primarily by disrupting microbial membranes through pore formation and chemotactic recruitment of immune cells. They are released at epithelial surfaces (airways, intestine, urinary tract, etc.) and, in some cases, immune cells, acting as endogenous alarmins to amplify both innate and adaptive immunity. Beta-defensins have complex immunomodulatory properties, with evidence of both pro- and anti-inflammatory actions that depend on disease context and expression levels. They are being actively investigated as lead compounds for novel antibiotics and immunomodulatory therapies, with emerging roles as biomarkers for infection, inflammation, and certain cancers (e.g., decreased hBD1 in colon cancer). Expression and activity are tightly regulated by pathways such as EGFR-MAPK in epithelial tissues. Safety and delivery remain important therapeutic challenges, as excessive or dysregulated defensin activity may lead to cytotoxicity and autoimmunity.

Other names

Beta-defensinβ-defensinhuman beta-defensinhBD-1hBD-2hBD-3antimicrobial peptideAMPhost-defense peptide

Drugs/analogs mimic beta-defensin mechanisms: direct antimicrobial activity (membrane disruption), immunomodulation (chemotaxis, cytokine induction), and potential anti-tumor effects